2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
生物活性
Description
In Vivo
In Vitro
化合物的使用
Kinase Assay
Cell Assay
Animal Administration
参考文献
OC000459 is a once-daily oral CRTH2 antagonist in Phase IIb clinical trials that has demonstrated efficacy in asthma, allergic rhinitis and allergic conjunctivitis along with an excellent safety profile. In private groups it was deciced that OC000459 would be the best available safe antagonist that also could be used For topical use. For the detailed information about the solubility of OC000459 in water, the solubility of OC000459 in DMSO, the solubility of OC000459 in PBS buffer, the animal experiment（test） of OC000459,the in vivo,in vitro and clinical trial test of OC000459,the cell experiment（test） of OC000459,the IC50, EC50 and Affinity of OC000459, please contact DC Chemicals.
